Sanofi ADR

Sanofi ADR

Yahoo Finance • 4 days ago

SA Asks: How could Trump's new executive order impact vaccine makers?

[Merck & Co. headquarters in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Earlier this month, President Donald Trump announced an executive order aimed at changing the number and timing of vaccines recommended for... Full story

Yahoo Finance • 5 days ago

HHS seeking public input on vaccine recommendation categories

[US Department of Health and Human Services] * HHS has issued a formal Request for Information that seeks public input on the categories used in federal vaccine recommendations and how shared decision-making between patients and doctors... Full story

Yahoo Finance • 5 days ago

Lawmakers ask FDA to scrutinize Chinese trials amid deaths - report

[capsules showcases the flag of United State of America and China] * Two Republican congressmen are asking FDA Acting Commissioner Kyle Diamantas to place greater scrutiny on clinical trial data from China, including not accepting data... Full story

Yahoo Finance • 5 days ago

Making Drugs With AI: Biopharma Giants Gear Up For New Arena

The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development. Continue Reading... Full story

Yahoo Finance • 6 days ago

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Quick Read SPTX's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for MDD and topline results expected in 1H 2027. BMY previously paid $14 billion for Karuna Therapeutics, co-founded by Seap... Full story

Yahoo Finance • 7 days ago

Billionaire Ken Griffin Increased His Position in This Dividend King by 547%

Billionaire hedge fund manager Ken Griffin was in the news after he scooped up most of the public stock portfolio formerly held by Situational Awareness late last month. In what was otherwise a bad month for hedge funds, Griffin's Citadel... Full story

Yahoo Finance • 7 days ago

Trump expected to nominate White House aide Heidi Overton as FDA commissioner

[FDA Headquarters] President Donald Trump is expected to tap Heidi Overton, a top aide at the White House’s Domestic Policy Council, to serve as the next commissioner of the Food and Drug Administration, according to multiple media report... Full story

Yahoo Finance • 8 days ago

European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were trending lower in late Tuesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 9 days ago

AimwellBio Secures Patented Behavioral AI Portfolio Backed by Oxford Science and Sanofi Pilot; Inventor Dr. Chris A. Jones Joins Board of Advisors

Executed IP assignment brings a decade of technology, published research, and pharma-tested behavioral engagement capabilities into AimwellBio as the Company expands its scientific and medical advisory network MIAMI, FL / ACCESS Newswire... Full story

Yahoo Finance • 14 days ago

U.K. regulator reaffirms safety of childhood vaccination

[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed... Full story

Yahoo Finance • 14 days ago

InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001

IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell l... Full story

Yahoo Finance • 15 days ago

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchi... Full story

Yahoo Finance • 20 days ago

Antipodes Exited Sanofi (SNY) After Repeated Pipeline Setbacks

Antipodes Partners published its "Antipodes Global Strategy" second-quarter 2026 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. The second q... Full story

Yahoo Finance • 21 days ago

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...

This article first appeared on GuruFocus. Net Loss: $194.3 million, or a loss of $1.36 per share, for the fiscal 2026 third quarter ended June 30, 2026. Revenue: Approximately $75 million for the quarter, up from $28 million in the prior... Full story

Yahoo Finance • 22 days ago

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Nurix Therapeutics, Inc. Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive appr... Full story

Yahoo Finance • 22 days ago

Sanofi's MenQuadfi Wins EC Approval For Use In Six Week Old Infants Against Meningococcal Disease

(RTTNews) - Sanofi (SNY) announced on Tuesday that the European Commission (EC) has approved an expanded indication for MenQuadfi for use in infants from six weeks of age to help protect against invasive Meningococcal disease caused by Nei... Full story

Yahoo Finance • 22 days ago

Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi Winthrop Industrie Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an... Full story

Yahoo Finance • 24 days ago

Sanofi (ENXTPA:SAN) Ends Amlitelimab Development For Atopic Dermatitis After Pipeline Review

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Sanofi (ENXTPA:SAN) has discontinued development of amlitelimab for atopic dermatitis following... Full story

Yahoo Finance • 27 days ago

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. Additionally, the launch of emerging th... Full story

Yahoo Finance • 27 days ago

Press Release: Sanofi’s half-year financial report for 2026

Sanofi’s half-year financial report for 2026 Paris, July 30, 2026. Sanofi announces that its half-year financial report for the period ending June 30, 2026, is now available online and has been filed with the French market regulator Autor... Full story